Department of Biochemical Diagnostics, Medical University Białystok, Waszyngtona 15A, Białystok 15-269, Poland.
J Ovarian Res. 2013 Jul 2;6(1):45. doi: 10.1186/1757-2215-6-45.
VEGF may play a role in the pathogenesis of cancer disease, for example in cell growth, proliferation and angiogenesis. In this study, we investigated plasma levels of this cytokine in comparison to plasma levels of a new biomarker - HE4 and the established tumor marker CA125 in ovarian cancer patients (100) as compared to control groups: patients with a benign ovarian tumor (80) and healthy subjects (50).
Plasma levels of VEGF were determined by ELISA, HE4 and CA125 by CMIA method.
The results showed that levels of VEGF, CA125 and HE4 were significantly higher in ovarian cancer (OC) patients as compared to the both control groups. VEGF has demonstrated as high as comparative markers values of the diagnostic sensitivity (SE), specificity (SP), the predictive values of positive and negative test results (PV-PR, PV-NR), and the area under the ROC curve (AUC) in early stages of cancer tested groups. The combined use of parameters studied resulted in the increase in the diagnostic criteria values and the AUC.
These findings suggest the usefulness of VEGF in the early diagnostics of ovarian cancer, especially in combination with CA125 and HE4, as a new biomarkers panel. Additionally, VEGF is the most useful tool in the diagnostics of locally advanced ovarian cancer without metastases. Investigated cytokine presented similar to HE4 usefulness in differentiation of OC according to its histopathlogical sub-type, and could be used especially in the diagnostics of endometrioid epithelial OC.
VEGF 可能在癌症的发病机制中发挥作用，例如在细胞生长、增殖和血管生成中。在这项研究中，我们研究了这种细胞因子的血浆水平，并与卵巢癌患者（100 例）与对照组（良性卵巢肿瘤患者 80 例和健康受试者 50 例）的新生物标志物 HE4 和已建立的肿瘤标志物 CA125 的血浆水平进行了比较。
通过 ELISA 测定 VEGF 水平，通过 CMIA 方法测定 HE4 和 CA125 水平。
结果表明，与两个对照组相比，卵巢癌（OC）患者的 VEGF、CA125 和 HE4 水平显著升高。VEGF 在癌症早期测试组中具有与比较标志物相似的诊断敏感性（SE）、特异性（SP）、阳性和阴性测试结果的预测值（PV-PR、PV-NR）以及 ROC 曲线下面积（AUC）值。联合使用研究参数可提高诊断标准值和 AUC。
这些发现表明 VEGF 在卵巢癌的早期诊断中有用，特别是与 CA125 和 HE4 联合使用时，作为一种新的生物标志物组合。此外，VEGF 是诊断无转移局部晚期卵巢癌的最有用工具。研究的细胞因子与 HE4 一样，在根据其组织病理学亚型区分 OC 方面具有相似的用途，尤其可用于诊断子宫内膜样上皮 OC。
